| DB ID | MyCo_3920 |
| Title | Diagnostic accuracy of (1→3)-β-D-glucan to predict Pneumocystis jirovecii pneumonia in non-HIV-infected patients |
| Year | 2020 |
| PMID | 32463392 |
| Fungal Diseases involved | Pneumocystis carinii pneumonia |
| Associated Medical Condition | non-HIV-AIDS-infected patients |
| Genus | Pneumocystis |
| Species | jirovecii |
| Organism | Pneumocystis jirovecii |
| Ethical Statement | Institutional review board of General Hospital Jesenice, Cesta maršala Tita 112, Jesenice, Slovenia, approved of General Hospital Jesenice approved the study under condition that patients’ data were anonymized. |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Biopsy |
| Sample source | Lower respiratory tract samples |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Slovenia |
| Cohort | One hundred and eight immunocompromised individuals with typical clinical picture for PCP and suspicious radiological findings were included in the study. Serum samples were taken to measure the values of (1→3)-β-D-glucan (Fungitell, Associates of Cape Cod, USA). Lower respiratory tract samples were obtained to perform direct immunofluorescence (DIF, MERIFLUOR® Pneumocystis, Meridian, USA) stain and real-time PCR (qPCR). |
| Cohort No. | 108 |
| Age Group | 53 ± 15 years |
| P Value | p<0.001 |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Pneumocystis jirovecii is a cause of Pneumocystis pneumonia (PCP) in immunocompromised patients. PCP most often occurs in human immune deficiency virus (HIV) infected patients associated with high pathogen burdens but also in non-HIV immunocompromised patients. The diagnosis is mainly based on clinical and radiographic examinations, which are in majority of cases inconclusive, so microscopic or molecular detection of P. jirovecii in lower respiratory tract samples are necessary. The mechanism by which Pneumocystis organisms induce lung inflammation remains incompletely understood, but studies imply that Pneumocystis spp. |
| Technique | Immunological assay |
| Analysis Method | Immunofluorescence |
| ELISA kits | None |
| Assay Data | FDA- Fungitell® assay (Fungitell, Associates of Cape Cod, USA). |
| Validation Techniques used | Fungitell assay, Immunofluorescence, qRT-PCR |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
